Pfizer
US CDC will not publish report showing COVID vaccine effectiveness
"Scientific reports are routinely reviewed at multiple levels to ensure they meet the highest standards before publication," said HHS spokesperson Andrew Nixon.
'When I grow up, I want to be like you': remembering Morris Kahn's most productive years - opinion
Grapevine, November 30, 2025: Mamdani complexities
MBS’s first Washington trip since 2018 brings new investments
Former Pfizer chief scientist joins Immunai’s board of directors
Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the appointment of Dr. Mikael Dolsten to its board of directors.
Former Pfizer R&D chief Mikael Dolsten joins Immunai’s board of directors
Dolsten brings decades of pharmaceutical leadership to advance AI-driven drug discovery.
Israel Bonds honors Pfizer CEO Albert Bourla for contributions to health, support for Israel
Bourla has received several honors from Israeli institutions in recognition of his support for Israel and his contributions to medicine.
Grapevine January 31, 2024: The courage of her convictions
Movers and shakers in Israeli society.
Israeli-American blueprint for future pandemic medications
An open-access format for drug discovery is helping design medications at lower prices against potential viral threats to mankind.
Antibiotic shortages expected to worsen syphilis epidemic - NYT
Pfizer announced that there would be shortages of Bicillin L-A last month. Bicillin L-A is a long-acting injectable antibiotic that is also known as penicillin G benzathine.
Pfizer scraps one weight loss drug in race to develop Ozempic rival
The company's shares fell 3.5% in volatile premarket trading on Monday as Pfizer said it would stop developing its therapy lotiglipron.
Pfizer expects to run out of antibiotic supply soon
Supply of the drug, Bicillin L-A, is expected to be exhausted by the end of this quarter, the company said in a letter to the US health regulator dated Monday.
Pfizer pouring COVID profits into cancer battle, CEO Bourla says
The COVID products drove Pfizer's revenue to record levels, topping $100 billion in 2022 and $80 billion in 2021.
Got migraines? FDA approved Pfizer's nasal spray treatment
Every day, there are 40,000 migraine attacks in Israel. This new Pfizer treatment could help
